Conference report: Six-and-a-half-year outcomes for nivolumab in combination with ipilimumab continue to demonstrate durable long-term survival benefits in patients with advanced melanoma in CheckMate -067 trial

With a minimum follow-up of 6.5 years, median overall survival (OS) was 72.1 months with the combination regimen, the longest reported median OS in a phase 3 advanced melanoma trial (compared with 36.9 months with nivolumab and 19.9 months with ipilimumab monotherapy).

Source:

Biospace Inc.